GET MY SAVINGS CARD

Tris Pharma Co-pay Savings Program

With the Tris Savings program, you may be eligible to save on your out-of-pocket costs for Dyanavel XR, Quillivant XR, or QuilliChew ER

ELIGIBLE PATIENTS MAY
PAY AS LITTLE AS $25*
ON THEIR PRESCRIPTION
Tris Savings Card Example

* With the Tris Co-pay Savings Card, eligible commercially-insured and cash-paying patients can lower their out-of-pocket costs for their prescription. Eligible patients may pay as little as $25 on each prescription. Program benefit calculated on FDA-approved dosing. A valid Prescriber ID# is required on the prescription. Patients with questions about the Tris Savings offer should call 1-888-840-7006. Terms and Conditions available at coupon.trisadhd.com/terms.

GET MY SAVINGS CARD

First, we need to verify that you are eligible for the Tris Pharma Savings Card. Please fill in the information below. Items marked with (*) are required.

You must be 18 years of age or older to download a savings offer.
Please select your response.
Please enter Parent/Caregiver first name.
Please enter Parent/Caregiver last name.
Please select your response.
The Tris Savings program is only available to commercially-insured patients who reside in the United States and US territories. If you have questions or need further assistance, please call 1-888-840-7006.
Please enter your first name.
Please enter your last name.
Please enter your address.
Please enter your address2.
Please enter your city.
Please select your state.
Please enter your ZIP.
Please ensure your email address is in the correct format: user@domain.com
Email and Confirm Email are not matched.
Please ensure your mobile phone number is in the correct format.

By providing my mobile number, completing enrollment, and replying YES to the text message sent, I understand I will be receiving real-time prescription status alerts and program updates via text message to the number provided. You may unsubscribe from the Mobile Program at any time by texting STOP to 844-970-ADHD (2343). Msg & data rates may apply.


APPROVED USE

DYANAVEL XR, Quillivant XR, and QuilliChew ER are central nervous system (CNS) stimulant prescription medicines used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years and older. These medicines may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if DYANAVEL XR, Quillivant XR, and QuilliChew ER are safe and effective in children under 6 years of age.

IMPORTANT SAFETY INFORMATION

DYANAVEL XR, Quillivant XR, and QuilliChew ER are federally controlled substance (CII) because they can be a target for people who abuse prescription medicines or street drugs. DYANAVEL XR, Quillivant XR, and QuilliChew ER has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Keep these medicines in a safe place to prevent abuse and misuse. Selling or giving away these medicines may harm others and is against the law.

Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with DYANAVEL XR, Quillivant XR, and QuilliChew ER and will monitor you or your child during treatment. Tell your physician if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

DYANAVEL XR, or Quillivant XR and QuilliChew ER, should not be taken if you or your child are allergic to amphetamine or methylphenidate hydrochloride, respectively, or any of the ingredients in these medicines, or are taking or have taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI including the antibiotic linezolid and the intravenous medicine methylene blue.

DYANAVEL XR, Quillivant XR, and QuilliChew ER can cause serious side effects. Tell the doctor:

Common side effects of amphetamine products include:

  • dry mouth
  • decreased appetite
  • weight loss
  • stomach pain
  • nausea
  • trouble sleeping
  • restlessness
  • extreme mood changes
  • dizziness
  • increased heart rate
  • dry mouth
  • decreased appetite
  • weight loss
  • stomach pain
  • nausea
  • trouble sleeping
  • restlessness
  • extreme mood changes
  • dizziness
  • increased heart rate

Common side effects of methylphenidate products include:

  • decreased appetite
  • trouble sleeping
  • nausea
  • vomiting
  • indigestion
  • stomach pain
  • weight loss
  • anxiety
  • dizziness
  • irritability
  • mood swings
  • fast heart beat
  • increased blood pressure
  • decreased appetite
  • trouble sleeping
  • nausea
  • vomiting
  • indigestion
  • stomach pain
  • weight loss
  • anxiety
  • dizziness
  • irritability
  • mood swings
  • fast heart beat
  • increased blood pressure

Talk to your doctor if you or your child have any side effects that bother you or do not go away.

Avoid drinking alcohol while taking DYANAVEL XR, Quillivant XR, or QuilliChew ER.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

See Full Prescribing Information for Dyanavel XR, Quillivant XR, and QuilliChew ER, including Boxed Warning about Abuse, Misuse and Addiction.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our online privacy policy for more information. While Tris Pharma makes reasonable efforts to include accurate, up-to-date information on the site, Tris Pharma makes no warranties or representations as to its accuracy. Tris Pharma assumes no liability for any errors or omissions in the content of the site.

DYANAVEL is a registered trademark of Tris Pharma, Inc. Quillivant XR and QuilliChew ER are registered trademarks of NextWave Pharmaceuticals, Inc. © 2024 Tris Pharma, Inc. All rights reserved. DXR.2343.PR      03/24